CytomX Therapeutics CTMX
NASDAQ CTMX
$2.44 +0.04 (+1.67%)
At close: Oct 22, 2026 · 4:00 PM EDT

CytomX Therapeutics (CTMX) Long-Term Debt Repayments (2014 - 2015)

Updated

CytomX Therapeutics (CTMX) reported Long-Term Debt Repayments of $40,000 for Q4 2015, down 88.2% from $339,000 a year earlier and down 98.3% from the prior quarter.

Analysis

CytomX Therapeutics (CTMX) Long-Term Debt Repayments (2014 - 2015) Analysis & Trends

For FY2015, CytomX Therapeutics posted Long-Term Debt Repayments of $3.07 million, up 144.2% from FY2014.

  • By year, Long-Term Debt Repayments came in at $1.26 million in FY2014 (+73.5%) and $724,000 in FY2013.
  • Per Business Quant data, the three quarters before Q4 2015 came in at $2.31 million (Q3 2015), $362,000 (Q2 2015) and $356,000 (Q1 2015).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 1.00 Mn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 2.00 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 2.46 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 17.00 Mn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 CytomX Therapeutics 533.12 Mn -424.55 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 40,000.00
Sep 30, 2015 2.31 Mn
Jun 30, 2015 362,000.00
Mar 31, 2015 356,000.00
Dec 31, 2014 339,000.00
API Access

CytomX Therapeutics Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=CTMX&period=max&api_key=YOUR_API_KEY